ABUS
Arbutus Biopharma Corp
4.90$
-0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 258.0% | 207.1% | 4,086.7% | 586.0% | 981.4% | 958.3% | 686.7% | 16.0% | 3.7% | 406.3% | 22.4% | 2.6% | |
| -158.0% | -107.1% | -3,986.7% | -486.0% | -881.4% | -858.3% | -586.7% | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% | |
| 258.0% | 207.1% | 4,086.7% | 586.0% | 981.4% | 958.3% | 713.6% | 596.1% | 216.3% | 406.3% | 875.7% | 179.2% | |
| 58.0% | 106.3% | 2,626.7% | 150.5% | 271.2% | 294.9% | 214.7% | 156.0% | 45.7% | 123.9% | 358.3% | 112.9% | |
| 319.3% | 315.7% | 6,786.7% | 755.1% | 1,289.8% | 1,535.7% | 249.3% | 769.1% | 267.8% | 530.5% | 1,336.7% | 289.5% | |
| -220.0% | -411.4% | -32,773.3% | -1,036.4% | -1,522.0% | -2,394.0% | -836.1% | -669.1% | -167.8% | -430.5% | -1,236.7% | -192.1% | |
| 5.7% | 2.7% | 92.7% | 2.4% | 3.4% | 35.1% | 58.0% | 26.0% | 4.4% | 2.5% | 2.2% | 0.7% | |
| -258.0% | -310.8% | -32,606.7% | -1,015.9% | -1,040.7% | -2,767.9% | -922.0% | -693.9% | -166.6% | -401.6% | -1,133.0% | -237.9% | |
| 0.7% | -65.1% | -7,000.0% | -227.1% | -72.9% | -210.5% | 21.2% | 10.0% | 11.4% | 0.0% | – | – | |
| -258.7% | -245.7% | -25,606.7% | -788.8% | -967.8% | -2,557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1,133.0% | -237.9% | |
| -216.3% | -308.4% | -32,538.3% | -994.8% | -999.2% | -2,699.1% | -835.3% | -652.0% | -158.5% | -391.3% | -1,108.5% | -234.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.